Tammy Huang

Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation

Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice